書籍詳細

総論

P.6 掲載の参考文献

• 1) 祖父江友孝:21世紀の肺癌の動向. Annual Review呼吸器 (工藤翔二, 土屋了介, 金沢 実, 他編), pp118-125, 中外医薬社, 2002

• 2) Sobue T, Ajiki A, Tsukuma H, et al:Trends of lung cancer incidence by histologic type:A population-based study in Osaka, Japan. Jpn J Cancer Res 90:6-15, 1999

• 3) Sobue T, Yamamoto S, Hara M, et al:Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women:the JPHC study. Int J Cancer (in press)

• 4) World Cancer Research Fund/American Institute for Cancer Research:food, nutrition and prevention of cancer:a global perspective. American lnstitute for Cancer Research, Washington DC, 1997.

• 5) Pope CA III, Burne Rt, Thun MJ, et al:Lung Cancer, Cardiopulmonary Mortality, and Long-term Exposure to Fine Particulate Air Pollution. Jama 287:1132-1141, 2002.

• 6) Blot WJ, McLaughlin JK:Passive smoking and lung cancer risk:what is the story now? J Natl Cancer lnst 90:1416-1417, 1998

• 7) Lubin JH, Boice JD Jr:Lung cancer risk from residential radon:meta-analysis of eight epidemiologic studies. J Natl Cancer Inst 89:4957, 1997

P.11 掲載の参考文献

• 1) 日本肺癌学会編:臨床・病理 肺癌取扱い規約改訂第 5版, pp91-140, 金原出版, 東京, 1999

• 2) Travis WD, Colby TV, Corrin R, et al:World Health Organization International Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours. Springer, Berlin, 1999

• 3) Noguchi M, Morikawa A, Kawasaki M, et al:Small adenocarcinoma of the lung. Cancer 75:2844-2852, 1995
  pubmed

• 4) Yokose T, Suzuki K, Nagai K, et al:Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3cm or less in diameter. Lung Cancer 29:179-188, 2000
  pubmed

• 5) Travis WD, Linnoila IL, Tsokos MG, et al:Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1:529-533, 1991

• 6) Travis WD, Rush W, Flieder DB, et al:Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22:934-944, 1998
  pubmed

P.17 掲載の参考文献

• 1) Mabry M, Nelkin BD, Baylin SB:Evolutionary model of lung cancer. Lung cancer:Principles and practice (ed, Pass HI, Mitchell JB, Johnson DH, et al), pp133-142, Lippincott-Raven Publishers, Philadelphia, 1996

• 2) Sekido Y, Fong KM, Minna JD:Molecular biology of lung cancer. Cancer:Principles and practice of oncology (ed, DeVita, Jr. VT, Hellman S, Rosenberg SA), six edition, pp917-925, Lippincott-Raven Publishers, Philadelphia, 2001

• 3) Sidransky DS:Clinical implications of the p53 gene. Annu Rev Med 47:285-301, 1996

• 4) Levine AJ:p53, the cellular gatekeeper for growth and division. Cell 88:323-331, 1997
  pubmed

• 5) Harris CC:Structure and function of the p53 tumor suppressor gene:clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455, 1996
  pubmed

• 6) Swisher SG, Roth JA, Nemunaitis J, et al:Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91:763-771, 1999
  pubmed

• 7) Benedict WF, Xu H-J, Hu S-X, et al:Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 85:988-993, 1990

• 8) Weinberg RA:The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995
  pubmed

• 9) Sherr CJ:Cancer cell cycles. Science 274:1672-1677, 1996
  pubmed

• 10) Rodenhuis S, Slebos RJC:Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665S-2669S, 1992

• 11) Johnson BE:The Role of MYC, JUN, and FOS oncogenes in human lung cancer. Lung cancer:Principles and practice (ed, Pass HI, Mitchell JB, Johnson DH, et al), pp83-98, Lippincott-Raven Publishers, Philadelphia, 1996

• 12) Hiyama K, Hiyama E, Ishioka S, et al:Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87:895-902, 1995
  pubmed

P.21 掲載の参考文献

• 1) Mountain CF:Revisions in international system for staging lung cancer. Chest 111:1710-1717, 1997
  pubmed

• 2) UICC:TNM classification of mailgnant tumours (eds, Sobin LH, Wittekind CH), Fifth edition, Wiley-Liss, New York, 1997

• 3) Naruke T, Tsuchiya R, Kondo H, et al:Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification:The Japanese experience. Ann Thorac Surg 71:1759-1764, 2001
  pubmed

• 4) Ginsberg RJ:Continuing controversies in staging NSCLC:An analysis of the revised 1997 staging system. Oncology 12:51-54, 1998
  pubmed

• 5) Bronchogenic Carcinoma Cooperative Group of the Society of Pneumology and Thoracic Surgery (GCCB-S). Clinical tumor size and prognosis in lung cancer. Eur Respir J 14:812-816, 1999

• 6) Mountain CF, Dresler CM:Regional lymph node classification for lug cancer staging. Chest 111:18-23, 1997

• 7) American Thoracic Society:Clinical staging of primary lung cancer. Amer Rev Resp Dis 127:659-664, 1983
  pubmed

• 8) Grunenwald D, Chevalier TL:Stage IIIA category of non-small-cell lung cancer:a new proposal. J Nat Cancer Inst 89:88-89, 1997

• 9) Deslauriers J, Brisson J, Cartier R, et al:Carcinoma of the lung. Evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg 97:504-512, 1989
  pubmed

• 10) 0kumura T, Asamura H, Suzuki K, et al:Intrapulmonary metastasis of non-small cell lung cancer:A prognostic assessment. J Thorac Cardiovasc Surg 122:244-248, 2001

• 11) Urschel JD, Urschel DM, Anderson TM, et al:Prognostic implications of pulmonary satellite nodules:Are the 1997 staging revisions appropriate? Lung Cancer 21:83-87, 1998
  pubmed

P.27 掲載の参考文献

• 1) 日本対癌協会. 対癌協会報 412:1-2, 1999

• 2) Mountain CF:Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
  pubmed

• 3) Colby TV, Wistuba II, Gazdar A:Precursors to pulmonary neoplasia. Adv Anat Pathol 5:205-215, 1998
  pubmed

• 4) Wistuba II, Behrens C, Milchgrub S, et al:Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18:643-650, 1999
  pubmed

• 5) Miyake M, Adachi M, Huang C, et al:A novel molecular staging protocol for non-small cell lung cancer. Oncogene 18:2397-2404, 1999

• 6) Rodenhuis S, Slebos RJ, Boot AJ, et al:Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48:5738-5741, 1988
  pubmed

• 7) Mitsudomi T, Steinberg SM, Oie HK, et al:Ras gene mutations in non-small cell lung cancer are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999-5002, 1991
  pubmed

• 8) Huang C, Taki T, Adachi M, et al:Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol 12:553-563, 1998

• 9) Slamon DJ, Leyland-Jones B, Shak, S et al:Use of chemotherapy plus a monoclonal, antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344:783-792, 2001

• 10) Kem JA, Schwartz DA, Nordberg JE, et al:p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184-5191, 1990

• 11) Harpole DH Jr, Herndon JE, Wolfe WG, et al:A prognostic model of recurrence and death in stage 1 non-small cell lung cancer utilizing presentation, hitopathology, and oncoprotein expression. Cancer Res 55:51-56, 1995
  pubmed

• 12) Merlo A, Herman JG, Mao L, et al:5'CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN 2/MTS l in human cancers. Nat Med 1:686-692, 1995

• 13) Rusin MR, Okamoto A, Chorazy M, et al:Intragenic mutations of the p16INK4, p15INK4B and p18 genes in primary non-small-cell lung cancers. Int J Cancer 65:734-739, 1996
  pubmed

• 14) Marchetti A, Buttitta F, Pellegrini S, et al:Alterations of p16 (MTS1) in node-positive non-small cell lung carcinomas. J Pathol 181:178-182, 1997
  pubmed

• 15) Huang C, Taki T, Higashiyama M, et al:p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Brit J Cancer 82:374-380, 2000
  pubmed

• 16) Morgan SE, Kastan MB:p53 and ATM:cell cycle, cell death, and cancer (ed, Vande Woude GF, Klein G). Adv Cancer Res 71:1-25, 1997

• 17) Takahashi T, Takahashi T, Suzuki H, et al:The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6:1775-1778, 1991

• 18) Baker SJ, Fearon ER, Nigro JM, et al:Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217-221, 1989
  pubmed

• 19) Cho Y, Gorina S, Jeffrey PD, et al:Crystal structure of a p53 tumor suppressor-DNA complex:understanding tumorigenic mutations. Science 265:346-355, 1994
  pubmed

• 20) Huang C, Taki T, Adachi M, et al:Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 16:2469-2477, 1998
  pubmed

• 21) Roth JA, Nguyen D, Lawrence DD, et al:Retrovirus-mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nature Med 2:985-991, 1996
  pubmed

• 22) Geradts J, Fong KM, Zimmerman PV, et al:Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5:791-800, 1999
  pubmed

• 23) Sekido Y, Ahmadian M, Wistuba II, et al:Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 16:3151-3157, 1998
  pubmed

• 24) Pavelic K, Kirzanac S, Cacev T, et al:Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas. Mol Med 7:442-453, 2001

• 25) Miyake M, Koyama M, Seno M, et al:Identification of the motility related protein, MRP-1 recognized by monoclonal antibody M31-15 inhibiting the cell motility. J Exp Med 174:1347-1354, 1991
  pubmed

• 26) Ikeyama S, Koyama M, Yamaoko M, et al:Suppression of cell motility and metastasis by transfection With human motility-related protein (MRP-1/CD9) DNA. J Exp Med 177:1231-1237, 1993

• 27) Miyado K, Yamada G, Yamada S, et al:Requirement of CD9 on the egg plasma membrane for fertilization. Science 287:321-324, 2000
  pubmed

• 28) Higashiyama M, Taki T, Ieki Y, et al:Correlation of motility related protein-1 (MRP-1/CD9) gene expression with poor prognosis of patients with non-small cell lung cancer. Cancer Res 55:6040-6044, 1995
  pubmed

• 29) Uchida S, Shimada Y, Watanabe G, et al:Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Brit J Cancer 79:1168-1173, 1999
  pubmed

• 30) Mori M, Mimori K, Shiraishi T, et al:Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 4:1507-1510, 1998
  pubmed

• 31) Miyake M, Nakano K Itoi S, et al:Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 56:1244-1249, 1996
  pubmed

• 32) Sho M, Adachi M, Taki T, et al:Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 79:509-516, 1998
  pubmed

• 33) Dong J-T, Lamb PW, Rinker-Schaeffer CW, et al:KAI-1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11. 2. Science (Washington DC) 268:884-886, 1995

• 34) Adachi M, Taki T, leki Y, et al:Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 56:1751-1755, 1996

• 35) Huang C, Kohno N, Ogawa E, et al:Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 153:973-983, 1998
  pubmed

• 36) Miyake M, Inufusa H, Adachi M, et al:Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery. Oncogene 19:5221-5226, 2000

• 37) Gall JG:Beginning of the end:origins of the telomere concept. In:Telomeres (ed, Blackburn EH, Greider CW) ,pp 1-10, 1995

• 38) Yashima K, Litzky LA, Kaise L, et al:Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 57:2373-2377, 1997

• 39) Arinaga M, Shimizu S, Gotoh K et al:Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. Ann Thorac Surg 70:401-405, 2000
  pubmed

P.35 掲載の参考文献

• 1) 日本肺癌学会編:臨床・病理 肺癌取扱い規約 改訂第5版, 金原出版, 東京, 1999

• 2) Schwartz M:A biomathematical approach to clinical tumor growth. Cancer 14:1272-1294, 1961

• 3) Usuda K, Saito Y, Sagawa M, et al:Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74:2239-2244, 1994
  pubmed

• 4) 清水邦彦, 山田耕三ほか:径 15mm 以下肺野微小腺癌のCT画像の解析; 病理形態学的分類との比較検討を中心に. 日呼吸会誌 36:672-678, 1998

• 5) Kuriyama K, Tateishi R, Doi O, et al:Prevalence of air bronchograms in small peripheral carcinomas of the lung on thin-section CT:comparison with benign tumors. AJR 156:921-924, 1991
  pubmed

• 6) 田中 学, 山田耕三ほか:径20mm以下の腺癌以外の肺野型肺癌-CT画像と病理所見の対比検討-. 肺癌 40:279-285, 2000

• 7) 山田耕三, 野村郁男ほか:Thin-section CT画像を用いた肺野小型病変と肺血管の解析. 肺癌 32:845-850, 1992

• 8) Noguchi M, Morikawa A, Kawasaki M, et al:Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75:2844-2852, 1995
  pubmed

• 9) 清水邦彦, 山田耕三, 斎藤春洋ほか:CT画像上ですりガラス様陰影を呈する微小肺野病変の質的診断-微小肺腺癌と異型腺腫様過形成との鑑別-. 綜合臨牀 50:2302-2310, 2001

• 10) 齋藤春洋, 山田耕三ほか:径10mm以下の腺癌およびその類似病変のthin-section CT画像. 臨床放射線 47:109-122, 2002

• 11) 奥泉美奈ら:径20mm以下の限局性すりガラス濃度領域を呈する肺野病変の鑑別診断-HRCT所見と病理像との対比-. 日本医放会誌 60:419-427, 2000

• 12) 石和直樹, 山田耕三ほか:肺癌の術前評価における縦隔リンパ節診断-Thin-section CT画像による精度向上とその限界-. 肺癌の臨床 3:389-394, 2000
  Medical*Online

• 13) Pieterman RM:Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000
  pubmed

P.42 掲載の参考文献

• 1) Fontana RS, Sunderson DR, Woolner LB, et al; Screening for lung cancer:a critique of The Mayo Lung Project. Cancer 67:1155-1164, 1991

• 2) Tockman MS:Survival and mortality from lung cancer in a screened population:The Johns Hopkins Study. Chest 89:324S-325S, 1986

• 3) Melamed MR, Flehinger BJ, Zaman MB, et al:Screening for early lung cancer:results of The Memorial Sloan-Kettering Study in New York. Chest 86:44-53, 1984
  pubmed

• 4) Kubik A, Parkin DM, Khlat, et al:Lack of benefit from semi-annual screening for cancer of the lung follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 45:26-33, 1990
  pubmed

• 5) Marcus PM, Bergstralh EJ, Fagerstrom RM, et al:Lung cancer mortarity in the Mayo Lung Project:impact of extended follow-up. J Natl Cancer Inst 92:1308-1316, 2000

• 6) Sobue T, Suzuki T, Naruke T, et al:Acase-control study for evaluating lung-cancer screening in Japan. Int J Cancer 50:230-237, 1992

• 7) Okamoto T, Suzuki T, Hasegawa H, et al l Evalustion of a clinic-based screening program for lung cancer with a case-control design in Kanagawa, Japan. Lung Cancer 25:77-85, 1999

• 8) Sagawa M, Tsubono Y, Saito Y, et al:Acase-control study for evaluating the efficacy of mass screening program for lung cancer in Miyagi prefecture, Japan. Cancer 92:58&594, 2001

• 9) Nishii K Ueoka H, Kiura K, et al:A case-control study of lung cancer screening in Okayama prefecture, Japan. Lung Cancer 34:325332, 2001

• 10) Tsukada H, Kurita Y, Yokoyama A et al:An evaluation of screening for lung cancer in Niigata prefecture, Japan:a population based case-control study. Br J Cancer 85:1326-1331, 2001
  pubmed

• 11) Nakayama T, Baba T, Suzuki T, et al:An evaluation of chest X-ray screening for lung cancer in Gunma prefecture, Japan:a population-based case-control study. E J Cancer 38:1380-1387, 2002

• 12) 日本公衆衛生協会編:平成12年度がん検診の適正化に関する調査研究報告書, 厚生省老人保健事業推進費等補助金 「新たな がん検診手法の有効性の評価」 (久道班), 3月, 2001

• 13) Sone S, Takashima S, Li F, et al:Mass screening for lung cancer with mobile spiral computed tomograhpy scanner. Lancet 351:1242-1245, 1998

• 14) Henschke C, McCauley DI, Yankelevitz DF, et al:Early lung cancer action project:overall design and findings from baseline screening. Lancet 354:99-105, 1999
  pubmed

• 15) Kaneko M, Kusumoto M, Kobayashi T, et al:Computed tomography screening for lung carcinoma in Japan. Cancer 89:2485-2488, 2000
  pubmed

• 16) 楠 洋子, 中山富雄, 鈴木隆一郎ほか:肺癌治療における新しいアプローチ 「小型肺癌の診断」. 第16回日本肺癌学会ワークショップ講演集 (清水信義編), pp44-52, 岡山, 2001

• 17) Sobue T, Moriyama N, Kaneko M, et al:Screening for lung cancer with low-dose helical computed tomography:Anti-Lung Cancer Association Project. J Clin Oncol 20:911-920, 2002
  pubmed

• 18) 遠藤正浩, 高田佳木, 大林加代子ほか:10mm以下の末梢小型肺癌に対する気管支鏡下擦過細胞診検査の意義. 気管支学 8:653-658, 1997
  Medical*Online

• 19) Charles S, White MD, Eric A, et al:Transbronchial needle aspiration-guidance with CT fluoroscopy. Chest 118:1630-1638, 2000

• 20) VanSonnenberg E, Casola G, Ho M, et al:Difficult thoracic lesions:CT-guided biopsy experience in 150 cases. Radiiol 167:457-461, 1988
  pubmed

• 21) 千場 博, 深井裕治, 瀬戸貴司ほか:肺野小腫性病変 (10mm以下) 191例に対する確定診断法の検討. 気管支学 8:663-665, 1997

• 22) 小林寿光:CTガイド下気管支鏡生検. 第13回肺癌ワークショップ記録集「小型肺癌の基礎と臨床」. 九州大学出版会, 九州, pp 57-63, 1999

• 23) Mitruka S, Landreneau RJ, Mack MJ, et al:Diagnosing the indeterminate pulmonary nodule:percutaneaus biopsy versus thoracoscopy. Surg 118:676-684, 1995

• 24) Westcott JL, Rao N, Colley DP:Transthoracic needle biopsy of small pulmonary nodules. Radiol 202:97-103, 1997

• 25) Tomiyama N, Mihara N, Maeda M, et al:CT-guided needle biopsy of small pulmonary nodules:value of respiratory gating. Radiol 217:907-910, 2000
  pubmed

• 26) 古泉直也, 酒井邦夫, 松月由子ほか:高分解能CTにおける肺腺癌の "淡い領域" の経時変化. 日本医放会誌 56:715-719, 1996

• 27) Hasegawa M, Sone S, Takashima S, et al:Growth rate of small lung cancers detected on mass CT screening. BJR 73:1252-1259, 2000
  pubmed

• 28) 町田 優, 瀬尾弘司, 河合 寛ほか:Multidetector-raw CTを用いた肺癌一次検診の試み. 胸部CT検診8:124-127, 2001

• 29) 中川 徹, 草野 涼, 名和 健ほか:胸部CT検診におけるコンピュータ読影支援システムの開発-胸部CT検診実施施設の立場から-. MEDIX34:33-37, 2001

• 30) Marcus PM:Lung cancer screening:an update. J Clin Oncol 19:83s-86s, 2001

• 31) Aberle DR, Gamsu G, Henschke CI, et al:A consensus statement of the Society of Thoracic Radiology:screening for lung cancer with helical computed tomography. J Thorac Imaging 16:65-68, 2001

• 32) 日本公衆衛生協会編:平成11年度がん検診の適正化に関する調査研究報告書, 厚生省老人保健事業推進費等補助金 「肺がん 検診における高速らせんCT法の効果評価研究」 (鈴木班), 2000年 3月

P.48 掲載の参考文献

• 1) Seijo LM, Stennan DH:Interventional pulmonology. N Engl J Med 344:740-749, 2001

• 2) Miyazu Y, Miyazawa T, Kurimoto N, et al:Endobronchial ultrasonography in the assessment of centrally located early stage lung cancer prior to photodynamic therapy. Am J Respir Crit Care Med 165:832-837, 2002

• 3) Miyazawa T, Yamakido M, Ikeda S, et al:Implantation of Ultraflex nitinol stents in malignant tracheobronchial stenoses. Chest 118:959-965, 2000
  pubmed

• 4) Miyazawa T, Arita K:Airway stenting in Japan. Respirology 3:229-234, 1998
  pubmed

• 5) Doi M, Miyazawa T, Mineshita M, et al:Three-dimensional bronchial imaging by spiral computed tomography as applied to tracheobronchial stent placement. J Bronchology 3:155-158, 1999

• 6) Miyazu Y, Miyazawa T, Iwamoto Y, et al:The role of endoscopic techniques, Laser-induced fluorescence bronchoscopy, and endobronchial ultrasonography in choice of appropriate therapy for bronchial cancer. J Bronchol 8:10-16, 2001

• 7) Lam S, MacAulay C, Palcic B:Detection and localization of early lung cancer by imaging techniques. Chest 103:12S-14S, 1993
  pubmed

• 8) Lam S, Kennedy T, Unger M, et al:Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 113:696-702, 1998
  pubmed

• 9) Kusunoki Y, Imamura F, Uda H, et al:Early detection of lung cancer with Laser-induced fluorescence endoscopy and spectrofluorometry. Chest 118:1776-1782, 2000
  pubmed

• 10) Becker HD, Herth F:Endobronchial ultrasound of the airways and the mediastinum. In:Interventional Bronchoscopy Prog Respire Res (Ed, Bolliger CT, Mathur PN), Basel, Karger 30:80-93, 2000

• 11) Kurimoto N, Murayama M, Yoshioka S, et al:Assessment of usefullness of endobronchial urtrasonography in determination of depth of tracheobrinchial tumor invasion. Chest 115:1500-1506, 1999

• 12) Kato H:Photodynamic therapy for early stage central type of lung cancer. Mayo Clin Proc 72:688-690, 1997
  pubmed

• 13) Kato H, Okunata T, Shimatani H:Photodynamic therapy for early stage bronchogenic carcinoma. J Clin Laser Med Surg 14:235-238, 1996

• 14) Furuse, K Fukuoka M, Kato H, et al:A prospective phase II study on photodynamic therapy with photophrin II for centrally located early-stage lung cancer. J Clin Oncol 11:1852-1857, 1993

• 15) Sutedja T, Lam S, LeRiche JC, et al:Response and pattern of failure after photodynamic therapy for intraluminal stage I Iung cancer. J Bronchol:295-298, 1994

• 16) Edell ES, Cortese DA:Bronchoscopic phototherapy with hematoporphirin derivative for treatment of localized bronchogenic carcinoma; a 5year experience. Mayo Clin Proc 62:8-14, 1987

• 17) Dumon JF:A dedicated tracheobronchial stent. Chest 97:328-332, 1990
  pubmed

• 18) Dumon JF, Cavaliere S, Diaz-Jimenez JP, et al:Seven-year experience with the Dumon prosthesis. J Bronchol 3:6-10, 1996

• 19) Dumon JF, Dumon MC:Dumon-Novatech Y-stents; A four-year experience with 50 tracheobronchial tumors involving the carina. J Bronchol 7:26-32, 2000

• 20) Becker HD:Stenting of the central airways. J Bronchol 2:98-106, 1995

• 21) Herth F, Becker HD, LoCicero J, et al:Successfull bronchoscopic placement of tracheobronchial stents without fluoroscopy. Chest 119:1910-1912, 2001

P.52 掲載の参考文献

• 1) Graham EA, Singer JJ:Successful removal of an entire lung for carcinoma of the bronchus. JAMA 101:1371-1374, 1933

• 2) 小沢凱夫:肺切除. 日外会誌 42:1863-1944, 1942

• 3) 羽田圓城:拡大郭清の手技と成績. 診断と治療 83:2119-2125, 1995
  Medical*Online

• 4) Yoshino I, Yokoyama H, Yano T, et al:Comparison of the surgical results of lobectomy with bronchoplasty and pneumonectomy for lung cancer. J Surg Oncol 64:32-35, 1997
  pubmed

• 5) Khan IH, McManus KG, McCraith A et al:Muscle sparing thoracotomy:a biomechanical analysis confirms preservation of muscle strength but no improvement in wound discomfort. Eur J Cardiothorac Surg 18:656-661, 2000
  pubmed

• 6) Dartevelle PG, Khalife J, Chapelier A, et al:Tracheal sleeve pneumonectomy for bronchogenic carcinoma; report of 55 cases. Ann Thorac Surg 46:68-72, 1988
  pubmed

• 7) Yokoi K, Matsuguma H, Anraku M:Extrapleural pneumonectomy for lung cancer with carcinomatous pleuritis. J Thorac Cardiovasc Surg 123:184-185, 2002
  pubmed

• 8) Lung Cancer Study Group:Randomized trial of lobectomy versus limited resection for TINO non-small cell lung cancer. Ann Thorac Surg 104:615-623, 1995

• 9) Kodama K, Doi O, Higashiyama M, et al:Intentional limited resection for selected patients with TINOMO non-small-cell lung cancer; a single-institution study. J Thorac Cardiovasc Surg 114:347-353, 1997

• 10) Roviaro G, Valoni F, Rebuffat C, et al:Videothoracoscopic staging and treatment of lung cancer. Ann Thoracic Surg 59:971-974, 1995

• 11) Ginsberg RJ:A cautionary note. Ann Thoracic Surg 56:801-803, 1993
  pubmed

• 12) Buhr J, Hurtgen M, Kelm C, et al:Tumor dissemination after thoracoscopic resection for lung cancer. J Thorac Cardiovasc Surg 110:855-856, 1995
  pubmed

• 13) Yoshino I, Ushijima C, Tomiyasu M, et al:Unique Mini-thoracotomy assisted by videothoracoscopy facilitates a maximal view even with a minimal wound for resection of primary lung cancer. Surg Endosc 16:148-150, 2002

• 14) Miller AB, Fox W, Tall R:Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet 2:501-505, 1969
  pubmed

• 15) Shields TW, Higgins GA, Matthews MJ, et al:Surgical resection in the managementof small cell carcinoma of the lung. J Thoracic Cardiovasc Surg 84:481-488, 1982

• 16) lchinose Y, Hara N, Ohta M:Comparison between resected and irradiated small cell lung cancer in patients in stage 1 through IIIa. Ann Thorac Surg 53:95-100, 1992

• 17) 渡辺洋宇:小細胞癌に対する手術療法. 癌の臨床 41:1337-1386, 1995

P.56 掲載の参考文献

• 1) PORT Meta-analysis Trialists Group:Post operative radiotherapy in non-small cell lung cancer:systemic review and meta-analysis of individual patient data from nine randomized control trials. Lancet 352:257-263, 1998

• 2) Dosorets DE, Katin MJ, Blitzer PH, et al:Radiation therapy in the management of medically inoperable carcinoma of the lung:results and implications for future treatment strategies. International Journal of Radiation Oncology, Biology, Physics 24:3-9, 1992

• 3) Gauden S, Ramsay J, Tripconv L:The curative treatment by radiotherapy alone of stagel non-small cell carcinoma of the lung. Chest 108:12781282, 1995

• 4) Dautzenberg B, Arriagada R, et al, for the Groupe d'Etude et de Cancer Bronchiques:A controlled study of postoperative radiotherapy for patients with completely resected non-small cell lung carcinoma. Cancer 86:265-273, 1999

• 5) Keller SM, Adak S, Wagner H, et al:A randomized nial of postoperative adjuvant therapy in complete resected stageII-IIIA non-small-cell cancer. New England Journal of Medicine 343:1217-1222, 2000

• 6) Inculet R, Scott C, Dar AR, et al:Phase III study comparing chemotherapy and radiation therapy with preoperative chemotherapy and surgical resection in patients with non-small cell lung cancer with spread to mediastinal lymph nodes:a Radiation Therapy Oncology Group study (RTOG S9-01). Lung Cancer 18:65, 1997

• 7) Non-small Cell Lung Cancer Collaborative Group:Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899, 1995

• 8) Furuse K, et al:Phase III study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 13:869, 1995
  pubmed

• 9) Saunders M, Dische S, Barrett A, et al:Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer:a randomized multicentre trial. Lancet 350:161-165, 1997
  pubmed

• 10) Langendijk JA, ten Velde GP, Aaronson NK, et al:Quality of life after palliative radiotherapy in non-small cell lung cancer:a prospective study. International Journal of Radiation Oncology, Biology, Physics 47:149-155, 2000
  pubmed

• 11) Loeffler JS, Koov HM, Wen PY, et al:The treatment of recurrent brain metastases with stereotactic radiosurgery. Journal of Clinical Oncology 8:576-582, 1990

• 12) Pignon JP, Arriagada R, Ihde DC, et al:A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New England Joumal of Medicine 327:1618-1624, 1992

• 13) Turrisi AT III, Kim K, Blum R, et al:Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New England Joumal of Medicine 340:265-271, 1999

• 14) Arriagada R, Auperin A et al, on behalf of the PCIO Collaborative group:Prophylactic cranial irradiation overview (PCIO) in patients with small cell lung cancer (SCLC) in complete remission (CR). Proceedings of the American Society of Clinical Oncology 17:A1758, 457a, 1998

• 15) http://www.pmrc.tsukuba.ac.jp/臨床研究/lung.html

• 16) http://www.nirs.go.jp/newinfo/press/2001/03jyutiryo.htm

P.60 掲載の参考文献

• 1) Chemotherapy in non-small cell lung cancer; ameta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995

• 2) Postoperative radiotherapy in non-small-cell lung cancer; systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 352:257-263, 1998
  pubmed

• 3) Roth JA, Fossella F, Komaki R, et al:A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage III A non-small-cell lung cancer. J Natl Cancer Inst 86:673-680, 1994

• 4) Rosell R, Gomez-Codina J, Camps C, et al:Arandomized trial comparing preoperative chemotherapy plus surgery wilh surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153-158, 1994

• 5) Marino P, Preatoni A Cantoni A:Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis. Cancer 76:593-601, 1995
  pubmed

• 6) Pritchard RS, Anthony SP:Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125:723-729, 1996
  pubmed

• 7) Furuse K, Fukuoka M, Kawahara M, et al:Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
  pubmed

• 8) Curran WJ Jr, Scoll C, Langer C, et al:Phase III Comparison of Sequential vs Concurrent Chemoradiation for Patients (Pts) with Unresected Stage III Non Smal Cell Lung Cancer (NSCLC):Initial Report of Radiation Therapy Oncology Group (RTOG) 9410. Proc ASCO, 2000 (abstr 1891)

• 9) Shiller JH, Harrington D, Belani CP, et al:Arandomizedphase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). NEngl J Med 346:92-98, 2002

• 10) Kelly K, Crowley J, Bunn PA, et al:Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer; a Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001

• 11) Pignon JP, Arriagada R, Ihde DC, et al:A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:161-1624, 1992

• 12) Auperin A, Arriagada R, Pignon JP, et al:Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484, 1999

• 13) Turrisi AT, Kim K, Blum R, et al:Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently With cisplatin and etoposide. N Engl J Med 340:265-271, 1999
  pubmed

• 14) Murray N, Coy P, Pater JL, et al:Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11:336-344, 1993

• 15) Ihde DC, Pass HI, Glatstein ELI:Small cell lung cancer:staging evaluation and prognostic factors. Cancer, Principles&practice of oncology 4 (eds, De Vita VT, Hellman S, Rosenberg SA), pp911-941, Lippincott Williams&Wilkins, Philadelphia, 1997

• 16) Goldie JH, Coldman AJ, Gudauskas GA:Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982
  pubmed

• 17) Evans WK, Feld R, Murray N, et al:Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer; a multicenter, randomized trial by the National Cancer Institute of Canada. Ann Intem Med 107:451-458, 1987

• 18) Fukuoka M, Funlse K, Saijo N, et al:Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991

• 19) Roth BJ, Johnson DH, Einhom LH, et al:Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer; a phase III trial the Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992

• 20) Coldman AJ, Goldie JH:Impact of Dose-lntense Chemotherapy on the Development of Permanent Drug Resistanse. Semin Oncol 14:29-33, 1987

• 21) Murray N, Livingston R, Shepherd F, et al:Randomized study of CODE versus Alternating CAV/EP for Extensive-stage small cell lung cancer; An Intergrop Study of the National Cancer Institute of Canada Clinical Trials Group and Southwest Oncology Group. J Clin Oncol 17:2300-2308, 1999

• 22) Furuse K, Fukuoka M, Nishiwaki Y, et al:Phase III Study of lntensive Weekly Chemotherapy With Human Granurocyte Colony-Stimulating Factor Versus Standard Chemotherapy in Extensive-Disease small-cell lung cancer. J Clin Oncol 16:2126-2132, 1998

• 23) Noda K, Nishiwaki Y, Kawahara M, et al:The Japan Clinical Oncology Group, Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
  pubmed

P.66 掲載の参考文献

• 1) 江口研二:がん治療におけるインフォームドコンセント. 臨床腫瘍学, 日本臨床腫瘍研究会編 (西篠長宏編), pp396-413, 癌と化学療法社, 東京, 1996

• 2) John L:Experimental therapy or Quackery:What's the difference? Understanding Cancer, pp191-204, Harper&Row Publishers, New York, 1987

• 3) 星野一正:インフォームドコンセント, 丸善ライブラリー232, 丸善, 東京, 平成9年

• 4) Declaration of Helsinki:Recommendations guiding medical doctors in biochemical research involving human subjects (光石忠 敬訳, ヘルシンキ宣言 [世界医師会総会, ヘルシンキ1964, 東京1975, ベニス1983, ホンコン1989 改訂版]. 臨床評価 22:289-291, 1994)

• 5) OPRR Protecting Human Research Subjects, Institutional Review Board Guidebook. US Department of Health and Human Services, Pubic Health Service, National Institute of Health, 1993

• 6) Rフェイドン, Tビーチャム:インフォームドコンセント (酒井忠明, 秦洋一訳), みすず書房, 東京, 1995

• 7) 厚生省健康政策局総務課監修, 柳田邦男編:元気が出るインフォームドコンセント, 中央法規, 東京, 1996

• 8) Girgis A, Sanson-Fisher RW:Breaking bad news:consensus guidelines for medical practitioners. J Clin Oncol 13:2449-2456, 1995
  pubmed

• 9) Okamura H, Uchitomi Y, Kakizoe T:Guidelines for Telling the truth to cancer patients, JJCO 1998
  pubmed

• 10) 江口研二編:がん医療での臨床試験のインフォームドコンセント, 南江堂 東京, 1998

• 11) 兵頭一之介, 江口研二共訳:がん患者・家族との対話技術, 南江堂, 東京, 2001

• 12) 下山正徳ほか:臨床試験計画 (プロトコール) の作成, 実施, 並びに結果の統計解析とその評価に関するガイドライン. 第1部 癌の臨床42巻2号, 1996/第2部 癌の臨床42巻3号1996

• 13) 砂原茂一:臨床医学研究序説 方法論と倫理, 医学書院, 東京, 1988

• 14) 厚生省薬務局GCP研究会監修 医師のための治験ハンドブック, ミクス, 東京, 1997

• 15) Leventhal BG, Wittes RE:Research Methods in Clinical Oncology, Raven Press, New York, 1988

疾患編

P.74 掲載の参考文献

• 1) Hunter W:History of aneurysm of the aorta With some remarks on aneurysm in general. Medical Observations and lnquiries 1:323, 1757

• 2) Nesbitt JC:Superior vena cava syndrome:surgery and stents. In:Lung cancer:principles and practice (Eds, Pass HI, Mitchell JB, Johnson DH, et al), pp1056-1070, Lippincott Williams&Wilkins, Philadelphia, 2000

• 3) Escalante CP:Causes and management of superior vena cava syndrome. Oncology 7:61-68, 1993
  pubmed

• 4) 岸 和史, 佐藤守男:肺癌, 食道癌におけるIVRと放射線治療. 進行胸部悪性腫瘍による上大静脈, 気管気管支, 食道狭窄の stent治療と放射線治療の臨床的比較検討. 臨床放射線43:657-665, 1998

• 5) Stanford W, Doty DB:The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorc Surg 41:158-163, 1986

• 6) Goto K Kodama T, Hojo F, et al:Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer 82:1056-1061, 1998
  pubmed

• 7) Yamaguchi K, Aoyagi K, Urakami K, et al:Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-spechic enolase measurement. Jpn J Cancer Res 86:698-705, 1995
  pubmed

• 8) Takada M, Fukuoka M, Kawahara M, et al:Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer; results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060, 2002

• 9) Furuse K Fukuoka M, Kawahara M, et al:Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
  pubmed

• 10) Curran WJ, Scott C, Langer C, et al:Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer:Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:484a (abstr 1891), 2000

P.81 掲載の参考文献

• 1) Hoch W, McConVilleJ, Helms S, et al:Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Med 7:365-368, 2001

• 2) Fujii Y, Okumura M, Yamamoto S:Flow cytometric study of lymphocytes associated with thymoma and other thymic tumors. J Surg Res 82:312-318, 1999
  pubmed

• 3) 近藤和也, 門田康正ほか:胸腺上皮性腫瘍の全国アンケート調査. 日本呼吸器外科学会雑誌15:633-642, 2001

• 4) Okumura M, Ohta M, Tateyama H, et al:The world health organization histologic classification system reflects the oncologic behavior of thymoma. A clinical study of 273 patients. Cancer 94:624-632, 2002
  pubmed

P.86 掲載の参考文献

• 1) Bisbinas I, Langkamer VG:Pitfalls and delay in the diagnosis of Pancoast tumour presenting in orthopaedic units. Ann R Coll Surg Engl 82:291-295, 1999

• 2) Jones DR, Detterbeck FC:Pancoast tumors of the lung. Current Opinion in Pulmonary Medicine 4:191-197, 1998
  pubmed

• 3) 世界保健機関編. がんの痛みからの解放. 金原出版, 東京, 1987

• 4) 日本緩和医療学会編. がん疼痛治療ガイドライン, 真興交易, 2000

• 5) 吉岡伸吉郎, 則之敏生, 柴田 諭ほか:Pancoast症候群を呈し診断に苦慮した乳癌晩期再発の1例. 日臨外会誌 61:632-635, 2000

• 6) Dartevelle PG, Nacchiarini P:Surgical Management of Superior Sulcus Tumors. The Oncologist 4:398-407, 1999

• 7) York JE, Walsh GL, Lang FF, et al:Combined chest wall resection with vertebrectomy and spine reconstruction for the treatment of Pancoast tumors. J Neurosurg Spine 91:74-80, 1999

P.93 掲載の参考文献

• 1) 猿田享男:今日の診療11, 2001

• 2) 厚生省厚生科学研究補助金特定疾患対策研究事業, 間脳下垂体機能障害に関する調査研究班, 平成10年度総括研究事業報告書, p41

• 3) Annmarie Mcdonnell Keenan:Syndrome of inappropriate secretion of antidiuretic hormon in malignacy. Seminars in Oncology Nursing 15:160-167, 1999

• 4) Jeremy Shapiro, Gary E Richardson:Hyponatremia of malignancy. Critical Reviews in Oncology/Hematology 18:129-135, 1995

• 5) 石川三衛:Central salt-wasting syndrome (中枢性塩類喪失症候群). 診断と治療 (増刊号) 86:547, 1998

• 6) Lohr JW:Osmotic demyelination syndrome following correction of hyponatremia. Am J Med 96:408-413, 1994
  pubmed

• 7) List A, Hainsworth J, Dais B, et al:Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small cell lung cancer. J Clin Oncol 4:1191-1198, 1986

• 8) Gross A, Steinberg S, Reilly J, et al:Atrial natriuretic factor anc arginine vasopressin in tumor cell line from patients with lung cancer, and their relationship to serum sodium. Cancer Res 53:67-74, 1993

• 9) Ishikawa S, Saito T:Therapeutic ethcacy of vasopressin receptor antagonists. Intern Med 37:217-219, 1998
  pubmed

P.98 掲載の参考文献

• 1) 広川 裕:骨転移に対する放射線治療の適応と実際. ターミナルケア11:423-427, 2001

• 2) 富田勝郎ほか:脊椎転移癌の手術適応と術式選択. 整形・災害外科36:243-247, 1993

• 3) 守田哲郎, 長谷川和宏, 平田泰治ほか:脊椎転移がんに対する治療法の選択. 整形・災害外科41:1173-1180, 1998.

• 4) Harrington KD:Anterior decompression and stabilization of the spine as a treatment for vertebral collapse and spinal cord compression from metastatic malignancy. Clin Orthop 233:179-197, 1988

• 5) Kostuik JP, Errico TJ, Gleason TF, et al:Spinal stabilization of vertebral column tumors. Spine 13:250-256, 1988.
  pubmed

• 6) 本家好文:転移性骨腫瘍-非観血的治療を中心に-. Karkinos 3:329-334, 1990

• 7) Tong D, Gillick L, Hendrickson F, et al:The palliation of symptomatic osseous metastases:final results of the study by the radiation therapy oncology group. Cancer 50:893-899, 1982.

• 8) 片桐浩久ほか:転移性脊椎腫瘍に対する非手術的集学的治療の成績と手術適応について. 整形外科44:738-744, 1993.

• 9) 手島昭樹:放射線治療学 (井上俊彦編), pp395-413, 南山堂, 東京, 2001

• 10) Cotten A, Boutry N, Cortet B, et al:Percutaneous vertebroplasty:state of the art. RadioGraphics 18:311-320, 1998
  pubmed

• 11) Weill A, Chiras J, Simon JM, et al:Spinal metastases:indications for and results of percutaneous injection of acrylic surgical cement. Radiology 199:241-247, 1996
  pubmed

P.104 掲載の参考文献

• 1) 佐野圭司監修, 亀山正邦他編集, 中枢神経系のCT診断, 大脳腫瘍 (含側脳室), pp111-139, 医学書院, 東京, 1983

• 2) 森惟明編著, 栗坂昌宏他共著, 中枢神経疾患のMRI, 転移性脳腫瘍, pp88-96, シュプリンガー・フェアラーク東京株式会社, 東京, 1989

• 3) 青木茂樹編著. よくわかる脳MRI, 脳腫瘍, 秀潤社, 東京, pp38-77, 1998

• 4) 日本臨床腫瘍研究会編, 臨床腫瘍学, 68. 転移癌の治療 4. 脳転移, pp1667-1675, 癌と化学療法社, 東京, 1999

• 5) 高倉公朋監修, 山浦 晶編集, New Lecture3脳腫瘍第2版, XI. 転移性脳腫瘍, pp333-347, 篠原出版株式会社, 東京, 1996

• 6) 大川智彦編集, 癌放射線療法' 95, IV. 放射線治療に必要な画像診断の基礎 1. 脳, pp 197-206, 篠原出版株式会社, 東京, 1995

• 7) 西条長宏, 加藤治文監修, 専門医のためのがん治療学レビュー, 6. 各臓器癌の治療の進歩 14. 脳腫瘍, pp215-222, 総合医学社, 東京, 1997

• 8) 日本脳腫瘍統計委員会, Report of brain tumor registry of Japan (1969-1993), 日本脳神経外科学会, 2000

• 9) Bindal AK, Bindal RK, Hess KR, et al:Surgery versus Radiosurgery in the treatment of brain metastasis. J Neurosurg 84:748-754, 1996
  pubmed

P.109 掲載の参考文献

• 1) 神山宣彦:石綿の鉱物学と曝露の機会および肺内の石綿. 病理と臨床 7:676-685, 1989

• 2) 五島雄一郎, 山田和生ほか:労災補償. 臨床産業医学全書 2-1. 産業内科学循環器系/呼吸器系, pp849-861, 医歯薬出版, 東京, 1988

P.115 掲載の参考文献

• 1) Hrris NL, Jaffe ES, Diebold J, et al:The World Health Organization classification of hematologigal malignancies report of the clinical advisory committee meeting, Airilie House, Virginia, norvember 1997. Mod Pathol 13:193-207, 2000

• 2) The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classhication of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997

• 3) North LB, Herman IL, Lorigan JG:Thoracic lymphoma. Radiol Clin North Am 28:745-762, 1991

• 4) Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan:incidence of recently recognized entities. Pathol Int 50:696-702, 2000

• 5) Wernecke K, Vassallo P, Rutsch F:Tymic involvement in Hodgkin disease:CT and sonographic findings. Radiology 181:375-383, 1991

• 6) Lister TA, Crowther D, Sutcliffe SB, et al:Report of a Committee convened to discuss the evaluation and staging of patients with Hodgkin's disease:Cotswold meeting. J Clin Oncol 7:1630-1636, 1989

• 7) The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993

• 8) Rambaldi A, Lazzari M, Manzoni C, et al:Monitering of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99:856-862, 2002

• 9) Shipp MA, Abeloff MD, Antman KH, et al:International Consensus Conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma:report of the Jury. J Clin Oncol 17:403-429, 1999

P.120 掲載の参考文献

• 1) 宮本顕二:呼吸機能検査法?機能検査からみた呼吸器診断?. 呼吸器病New Approach, pp16-21, メヂカルビュー社, 東京

• 2) Fraser RG, Pare PD l Neoplasm of tracheobronchial Glands Diagnosis of diseases of the chest, pp1251-1268, W. B. Saunders Co., 2000

• 3) Maziak DE, Todd TR, Keshavjee SH, et al:Adenoid cystic carcinoma of the airway:Thirty-two-year experience. J Thorac Cardiovasc Surg 112:1522-1528, 1996
  pubmed

• 4) 中村治彦, 雨宮隆太ほか:気管, 気管支原発の腺様嚢胞癌の内視鏡所見の検討. 気管支学12:345-351, 1990

• 5) 川口知哉, 延山誠一, 細江重人ほか:種々の保存的治療を試みた気管原発腺様嚢胞癌の一剖検例. 日本呼吸器学会雑誌 38:812-816, 2000
  Medical*Online

• 6) Yousem SA Hochholzer L:Mucoepidermoid tumor of the lung. Cancer 60:1346-1352, 1987

• 7) Paladugu RR, Benfield JR, Pak HY, et al:Bronchopulmonary Kulchisky cell carcinomas:anew classification scheme for typical and atypical carcinoid. Cancer 55:1303-1311, 1985

• 8) Dweik RA, Patel SR, et al:Tracheal papillomatosis. J Bronchology 1:226227, 1994

• 9) Kawaguchi T, Matsumura A, Hosoe S, et al:Solitary squamous papilloma of the bronchus associated with human papilloma virus type 11. Intemal Medicine 38:817-819, 1999

P.127 掲載の参考文献

• 1) 日本呼吸器学会. COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン, 1999

• 2) 林 孝二:肺気腫症を有する肺癌症例の検討. 肺癌 38:317-321, 1998

• 3) 毛利昌史:肺気腫の外科的治療. IRYO 50:163-168, 1996
  Medical*Online

• 4) 毛利昌史:肺気腫シリーズ, 病態生理と肺減量手術の根拠. IRYO 51:240-242, 1997

• 5) 林 孝二:肺気腫の外科治療 (II):手術方法. IRYO 51:492-495, 1997
  Medical*Online

• 6) Hayashi K:Surgical Treatment for Patients With Lung Cancer Complicated by Severe Pulmonary Emphysema. The Japanese Journal of Thoracic and Cardiovascular Surgery 47:593-587, 1999

P.132 掲載の参考文献

• 1) 埴淵昌毅, 山口俊彦, 岡田達也ほか:特発性間質性肺炎 (IIP) 合併肺癌に対する肺癌治療後IIP急性増悪症例の臨床的検討. 肺癌 41:281-286, 2001

• 2) 佐藤篤彦:特発性間質性肺炎と関連疾患分科会総括報告. 厚生省特定疾患びまん性肺疾患調査研究班, 平成6年度研究報告書, pp 9-11, 1995

• 3) 竹内栄治, 山口俊彦, 森雅秀ほか:肺癌を合併した特発性間質性肺炎症例の臨床的検討. 日胸疾会誌 34:653-658, 1996

• 4) Chang AY, Kuebler JP, Tormey DC, et al:Phase II evaluation of a combination of Mitomycin C, Vincristine and Cis-platinum in advanced non-small cell lung cancer. Cancer 51:54-59, 1986

• 5) 吉村邦彦, 中谷龍王, 中森祥隆ほか:特発性間質性肺炎の急性増悪に関する臨床的検討ならびに考察. 日胸疾会誌 22:1012-1019, 1984

• 6) Dajczman E, Srolovitz H, Kreisman H, et al:Fatal pulmonary toxicity following oral etoposide therapy. Lung Cancer 12:81-86, 1995
  pubmed

• 7) 小倉 剛, 近藤有好, 佐藤篤彦ほか:特発性間質性肺炎における肺癌の合併とその臨床的特徴. 日胸疾会誌 35:294-299, 1997

• 8) 竹中 圭, 吉村明修, 岡野哲也ほか:特発性間質性肺炎 (IIP) 合併肺癌における肺癌治療に伴うIIP急性増悪の検討. 肺癌 39:955-962, 1999

• 9) Callahan WP, Sutherland JC, Fulton JK, et al:Acute diffuse interstitial fibrosis of the lungs. Arch Intern Med 91:468-473, 1952

• 10) 近藤有好:特発性間質性肺炎 (IIP) の疫学調査 (II). 厚生省特定疾患びまん性肺疾患調査研究班, 平成4年度研究報告書, pp11-18, 1993

• 11) 工藤翔二:特発性間質性肺炎 (IIP) の臨床診断基準第4次改定案の骨子が明らかに. Medical Tribune 34:25, 2001

• 12) Baumgartner KB, Samet JM, Stidley CA, et al:Cigarette smoking:A risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155:242-248, 1997
  pubmed

• 13) Iwai K, Mori T, Yamada N, et al:Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 150:670-675, 1994
  pubmed

• 14) Meyer EC, Liebow AA:Relationship of interstitial pneumonia honeycombing and atypical epithelial proliferation to cancer of the lung. Cancer 18:322-351, 1995

• 15) 松下 央:特発性間質性肺炎と肺癌. 病理と臨床11:178-182, 1993

• 16) Hojo S, Fujita J, Yamadori I, et al:Heterogenous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J 12:1404-1408, 1998
  pubmed

• 17) Uematsu K, Yoshimura A, Gemma A, et al:Aberrations in the FHIT gene in idiopathic pulmonary fibrosis. Cancer Res 61:8527-8533, 2001
  pubmed

• 18) Mori M, Kida H, Morishita H, et al:Microsatellite instability in transforming growth factor beta 1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 24:398-404, 2001
  pubmed

P.141 掲載の参考文献

• 1) Nagamoto N, Saito Y, Sato M, et al:Clinicopathological analysis of 19 cases of isolated carcinoma in situ of the bronchus. Am J Surg Pathol 17:1234-1243, 1993

• 2) Usuda K, Saito Y, Nagamoto N, et al:Relation between bronchoscopic findings and tumor size of roentgenographically occult bronchogenic squamous cell carcinoma. J Thorac Cardiovasc Surg 106:1098-1103, 1993
  pubmed

• 3) 佐藤雅美, 斎藤泰紀, 今井 督ほか:気管支鏡可視範囲外の末梢に局在するTX肺癌の検討-特に異型細胞の出現様式からみた局在部位診断法に関して-. 日臨細胞誌 26:903-913, 1987

• 4) Saito Y, Sato M, Sagawa M, et al:Multicentricity in Resected Occult Bronchogenic Squamous Cell Carcinoma. Ann Thorac Surg 57:1200-1205, 1994
  pubmed

• 5) Furuse K, Fukuoka M, Kato H, et al:Aprospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. J Clin Oncol 11:1852-1857, 1993

• 6) Saito M, Yokoyama A, Kurita Y, et al:Treatment of roentgenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low-dose-rate brachytherapy:second report. Int J Radiat Oncol Biol Phys 47:673-680, 2000
  pubmed

• 7) 佐藤雅美, 斎藤泰紀, 永元則義ほか:気管支における境界病変の診断とその細胞像. 日臨細胞誌 31:21-27, 1992

• 8) Sato M, Saito Y, Nagamoto N, et al:Diagnostic value of differential brushing of all branches of the bronchi in patients with sputum positive or suspected positive for lung cancer. Acta Cytol 37:879-883, 1994

• 9) 佐川元保, 斎藤泰紀, 遠藤千顕ほか:Tx肺癌例との鑑別が困難であった上気道癌-喀痰細胞診陽性で部位診断困難例に対する精査方法に関する考察-. 肺癌 31:259-263, 1991

• 10) Sato M, Sakurada A, Sagawa M, et al:Diagnostic results before and after introduction of autofluorescence bronchoscopy in patients suspected of having lung cancer detected by sputum cytology in lung cancer mass screening. Lung Cancer 32:247-253, 2001
  pubmed

• 11) Kurimoto N, Murayama M, Yoshioka S, et al:Assessment of usefulness of endobronchial ultrasonography in determination of depth of tracheobronchial tumor invasion. Chest 115:1500-1506, 1999
  pubmed

P.147 掲載の参考文献

• 1) 山田耕三, 礒部 威, 加藤雄二ほか:X線CT検査を契機に発見された肺野型肺癌のCT画像所見の検討. 肺癌 36:261-270, 1996

• 2) 礒部 威, 山田耕三ほか:1.0cm以下肺腺癌切除例のCT画像. 日胸疾会誌34:1084-1092, 1996

• 3) Ginsberg RJ, Rubinstein LV:Randomized trial of lobectomy versus limited resection for TINO non small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615-623, 1995

• 4) Mountain CF:Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
  pubmed

• 5) Niho S, Yokose T, Suzuki K, et al:Monoclonality of atypical adenomatous hyperplasia of the lung. Am J Pathol 154:249-254, 1999
  pubmed

• 6) Yamasaki M, Takeshima Y, Fujii S, et al:Correlation between genetic alterations and histopathological subtypes in bronchiolo-alveolar carcinoma and atypical adenomatous hyperplasia of the lung. Pathol Int 50:778-785, 2000
  pubmed

• 7) Noguchi M, Morikawa A, Kawasaki M, et al:Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75:28442852, 1995

• 8) Kaneko M, Eguchi K, Ohmatsu H, et al:Peripheral lung cancer:screening and detection with low-dose spiral CT versus radiography. Radiology 201:798-802, 1996
  pubmed

• 9) Sone S, Takashima S, Li F, et al:Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 351:1242-1245, 1998
  pubmed

• 10) Henschke CI, McCauley DI, Yankelevitz DF, et al:Early Lung Cancer Action Project:overall design and findings from baseline screening. Lancet 354:99-105, 1999
  pubmed

P.153 掲載の参考文献

• 1) 祖父江友孝:疫学増加をたどる肺癌の検証-欧米との比較. 内科 88:812-816, 2001

• 2) 小島哲弥, 山崎浩一, 岡本圭祐ほか:原発性肺癌の年齢別臨床的特徴の検討. 肺癌 40:751-757, 2000

• 3) 肺癌取り扱い規約, 第5版, 日本肺がん学会編, 金原出版, 1999

• 4) 荒木 厚, 室谷ゆかり, 井藤英喜:高齢者の全体像評価およびリスク評価高齢者のQOL評価法. 内科 87:229-233, 2001

• 5) Fentiman IS, Tireli U, Monfardini S, et al:Cancer in the elderly:why so badly treated? Lancet 335:1020-1022, 1990

• 6) Monfardini S, Yancik R:Cancer in the Elderly:meeting the challenge of an aging population. J Natl Cancer Inst 85:532-538, 1993
  pubmed

• 7) 上田 仁, 岡林寛, 隠土 薫ほか:80歳以上肺癌症例の検討. 肺癌41:313-317, 2001

• 8) Ginsberg RI:Preoperative assessment of the thoracic surgical patient:asurgeon's viewpoint, In:Thoracic Surgery (Eds, Pearson FG, et al), pp29-32, Churchill Livingstone, Philadelphia, 1995

• 9) Hayakawa K Mitsuhashi N, Katano S, et al:Radiation therapy for elderly patients With limited non-small cell lung cancer. Jpn Soc Ther Radiol Oncol 10:223-228, 1998

• 10) Lonardi F, Coeli M, Pavanato G, et al:Radiotherapy for non-small cell cancer in patients aged 75 and over:safety, effectiveness and possible impact on survival. Lung Cancer 28:43-50, 2000
  pubmed

• 11) 中野喜久雄, 平本雅彦, 金原正志ほか:高齢者III期非小細胞癌に対する放射線単独治療成績と予後の検討. 日呼吸会誌 37:276-281, 1999

• 12) Sekine I, Fukuda H, Kunitoh H, et al:Cancer chemotherapy in the elderly. Jpn J Clin Oncol 28:463-473, 1998
  pubmed

• 13) 野口善令:癌患者とのコミュニケーション-告知やインフォームド・コンセントを含むリエゾンとしての内科医の役割. Medicina 38:1537-1540, 2001

• 14) The Elderly Lung Cancer Vinorelbine Italian Study Group:Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:6672, 1999

• 15) Gridelli C, et al:The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase 3 trial-gemcitabine+vinorelbine vs vinorelbine and vs gemcitabine in elderly advanced NSCLC patients-. Proc Am Soc Clin Oncol 20:308a, 2001

• 16) Medical Research Council Lung Cancer Working Party:Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer:a stopped multicentre randomized trial. Lancet 348:563-566, 1996
  pubmed

• 17) Okamoto H, Watanabe K, Nishiwaki Y, et al:Phase II study of Area Under the Plasma-Concentration-Versus-Time-Curve-Based Carboplatin Plus Standard-Dose lntravenous Etoposide in Elderly Patients With Small-Cell Lung Cancer. J Clin Oncol 17:3540-3545, 1999
  pubmed

P.160 掲載の参考文献

• 1) Vlaudutie AO:Pleural effusion. Futura Publishing, New York, 1986

• 2) Light RW:Pleural Diseases. 3rd ed, pp129-153, Williams&Wilkins, Maryland, 1995

• 3) Pass HI:Malignant Pleural and Pericardial Effusions. Cancer, Principles and practice of oncology (ed, Devita Vr, Hellman S, Rosenberg SA), 5th ed, lippicott-Raven, Philadelphia, 1997

• 4) Luh KT, Yang PC, Kuo SH, et al:Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer, A randomized trial. Cancer 69:674-679, 1992
  pubmed

• 5) Walker-Renard PB, Yaughan LM, Sahn SA:Chemical Pleurodesis for Malignant Pleural effusions. Ann Intern Med 120:56-64, 1994

• 6) 瀧藤伸英ほか:非小細胞肺癌癌性胸膜炎に対するブレオマイシンvs OK-432 vs CDDP+VP-16療法の第2相無作為試験 (JCOG9515). 肺癌 41:431, 2001

• 7) Joan HS, David HP, Chandra PB, et al, for Eastern Cooperative Oncology Group:Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. N Engl J Med 346:68-73, 2002

• 8) Kohno N, et al:New serum indication of interstitial pneumonitis activity; Sialylatedcarbohydrate antigen KL-6. Chest 96:68-73, 1989

• 9) 阿部庄作, 本田泰人, 安藤正幸ほか:各種肺疾患における血清サーファクタント蛋白質-Aの臨床的意義. 日胸疾会誌 33:1219-1225, 1995

• 10) 新井基央ほか, 癌性胸膜炎におけるKL-6の有用性. 日呼吸会 39:108, 2001

• 11) 土屋良記, 大野城二:各種肺疾患における胸水中KL-6値の検討. 日呼吸会誌 38:200, 2000

• 12) Shijubo N, Honda Y, Fujishima T, et al:Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma. Eur Respir J 8:403-406, 1995
  pubmed

• 13) 石井芳樹, 北村 諭:局所麻酔下胸腔鏡検査の有用性. 結核 75:51-56, 2000

P.166 掲載の参考文献

• 1) 中島秀行, 島 智子, 臼杵則朗ほか:原発性肺クリプトコッカス症のCT所見の検討. 日本医学放射線学会雑誌 55:1032-1037, 1995

• 2) 岸 一馬, 本間栄, 黒崎敦子ほか:肺クリプトコッカス症の臨床病理学的検討-胸部CT所見と病理所見の比較を中心に. 日本呼吸器学会雑誌 38:670-675, 2000

• 3) 何澤信礼, 伊藤春海, 李 美於ほか:肺クリプトコッカス症の高分解能CT像. 画像病理対応とその鑑別診断:10症例の検討か ら. 臨床放射線 46:80-87, 2001

• 4) Fishman AP:Pulmonary diseases and Disorders, 2nd Ed, Volume 2, pp1769-1771, McGraw-Hill, New York, 1988

• 5) Fraser RG, Pare JAP, Pare PD, et al:Diagnosis of Diseases of the Chest II, 3rd Ed, pp975-985, W. B. Saunders, Philadelphia, 1989

• 6) 緒方賢一, 綿屋 洋, 諸岡三之ほか:肺クリプトコッカス症の2例. 本邦報告116例からみた原発性と続発性の比較. 気管支学 19:122-126, 19971

P.172 掲載の参考文献

• 1) Iuchi K, Aozasa K, Yamamoto S, et al:Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer 60:1771-1775, 1987

• 2) 青笹克之, 菅野祐幸, 三輪秀明:膿胸関連悪性リンパ腫. 分子呼吸器病3:439-443, 1999

• 3) 塩原順四郎, 初鹿野浩, 塩沢正俊:陳旧性穿孔性結核性膿胸と共存した原発性肺細網肉腫の1例. 日本胸部臨床 29:115-123, 1970

• 4) 有田健一:慢性膿胸関連リンパ腫の臨床-本邦報告87症例のまとめ-. 広島医学55:404-408, 2002

• 5) 亀崎 洋, 大野陽一郎, 天野博之ほか:膿胸壁に発生したびまん性大細胞性B細胞型悪性リンパ腫の3例. 臨床血液 31:511-515, 1990

• 6) 大道和宏, 有田健一, 土井正男ほか:陳旧性膿胸に合併した胸腔内原発悪性リンパ腫に関する臨床的検討. 日本胸部疾患学会雑誌 29:866-872, 1991

• 7) 小栗鉄也, 有田健一, 大道和宏ほか:Neuron-specific enolase の変動が治療効果判定に有用であった陳旧性結核性膿胸に合併した悪性リンパ腫の1例. 広島医学 45:1302-1304, 1992

• 8) 中島由槻, 和久宗明, 小島 玲ほか:慢性結核性膿胸の膿胸壁由来悪性リンパ腫の画像診断. 臨床放射線 40:63-72, 1995

• 9) 渋佐 隆, 田中裕士, 伊藤英司ほか:慢性膿胸壁から発生した胸膜悪性リンパ腫の1例-MRIの診断的有用性-. 日本胸部疾患学会雑誌 33:686-690, 1995

• 10) 深山正久:Epstein-Barr Virusと膿胸関連胸膜リンパ腫. 日本胸部臨床 54:9-17, 1995

• 11) 伊丹真紀子, 高木敏之:胸部・乳房のリンパ腫-発生年齢, AIDSとの関連など. 臨床放射線 46:1121-1128, 2001

• 12) 青笹克之, 高桑徹也, 中塚伸一:慢性炎症を基盤に発生する悪性リンパ腫. 日本内科学会雑誌 90:1019-1023, 2001

P.178 掲載の参考文献

• 1) 固形がん化学療法の直接効果判定基準. 日癌治療会誌 21:929-942, 1986

• 2) 原発性ならびに転移性肺腫瘍に対する効果判定基準肺癌取扱い規約 (改定第2版)

• 3) Oken MM, Creech RH, Tormey DC, et al:Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982

• 4) Green S, Weiss GR:Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992

• 5) WHO handbook for reporting results of cancer treatmen. Geneva (Switzerland), World Health Organization, Offset Publication, No48, 1979

• 6) Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment insolid tumors. J Natl Cancer Inst 92:205-216, 2000

• 7) Watanabe H, Sekine I, Yamamoto S, et al:Measuring response of non-small cell lung cancer to chemotherapy:comparison of unidimensional and bidimensional measurement. Proc Ann Meet Am Soc Clin Oncol 19:498a, 2000

• 8) Thiesse P, Ollivier L, Di Stefano-Louineau D, et al:Response rate accuracy in oncology trials:reasons for interobserver variability. J Clin Oncol 15:3507-3514, 1997
  pubmed

• 9) Watanabe H, Kunitoh H, Yamamoto S, et al:Analysis of inter-observer variability in tumor response evaluation according to RECIST 1(Response Evaluation Criteria in Solid Tumors) guideline. Proc Ann Meet Am Soc Clin Oncol 21:309a, 2002

P.183 掲載の参考文献

• 1) Rice TW, Adelstein DJ, Koka A, et al:Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. Ann Thorac Surg 60:586-591, discussion 591-592, 1995

• 2) Martini N, Flehinger BJ, Zaman MB, et al l Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 198:386-397, 1983

• 3) Pearson FG, DeLarue NC, Ilves R, et al:Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 83:1-11, 1982
  pubmed

• 4) Martini N, Kris MG, Flehinger BJ, et al:Preoperative chemotherapy for stage IIIa (N2) lung cancer:the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55:1365-1373, 1993
  pubmed

• 5) Ginsberg RJ:Neoadjuvant (induction) treatment for non-small lung cancer. Lung Cancer 12:33-40, 1995

• 6) Rosell R, Gomez-Codina J, Camps C, et al:Arandomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients With non-small-cell lung cancer [see comments]. NEngl J Med 330:153-158, 1994

• 7) Roth JA, Fossella F, Komaki R, et al:Arandomized trial comparing perioperative chmotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer [see comments]. JNatl Cancer Inst 86:673-680, 1994

• 8) Roth JA, Atkinson EN, Fossella F, et al:Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer [see comments]. Lung Cancer 21:1-6, 1998

• 9) Rosell R, Gomez-Codina J, Camps C, et al:Preresectional chemotherapy in stage IIIA non-small-cell lung cancer:a 7-year assessment of a randomized controlled trial see comments. Lung Cancer 26:7-14, 1999

• 10) Choi NC, Carey RW, Daly W, et al:Potential impact on survival of improved tumor downstaging and resection rate by preoperative twicedaily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 15:712-722, 1997
  pubmed

• 11) Eberhardt W, Wilke H, Stamatis G, et al:Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer:mature results of a phase II trial. J Clin Oncol 16:622-634, 1998
  pubmed

• 12) Pisters KM, Kris MG, Bunn PA Jr, et al:Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Semin Oncol 24:S12-41-S12-44, 1997

• 13) Depierre A, Milleron B, Moro-Sibilot D, et al:Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except TINO), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20:247-253, 2002

• 14) Burkes RL, Ginsberg RJ, Shepherd FA, et al:Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer:results of the Toronto Phase II Trial. J Clin Oncol 10:580-586, 1992
  pubmed

• 15) Darwish S, Minotti V, Crino L, et al:Aphase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer. Lung Cancer 12:71-78, 1995

• 16) Elias AD, Skarin AT, Gonin R, et al:Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol 17:26-36, 1994
  pubmed

• 17) Sugarbaker DJ, Herndon J, Kohman LJ, et al:Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 109:473-483, discussion 483-485, 1995

• 18) Strauss GM, Hemdon JE, Shermann DD, et al:Neoadjuvant chemotherapy and radiothrapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung:report of a Cancer and L? ukemia Group B phase II study. J Clin Oncol 10:1237-1244, 1992

• 19) Albain KS, Rusch W, Crowley JJ, et al:Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer l mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13:1880-1892, 1995

P.188 掲載の参考文献

• 1) Non-small cell lung cancer collaborative group:Chemotherapy in non-small cell lung cancer:Ameta-analysis using updated data on individual patients from 52 randomized clinical trials, Br Med J 311:899-909, 1995

• 2) Huisman C, Smit EF, Giaccone G, et al:Second-line chemotherapy in relapsing or refractory Non-small-cell lung cancer:Areview. J Clin Oncol 18:3722-3730, 2000

• 3) Sweeney CJ, Zhu J, Sandler AB, et al:Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group study E1594:A phase III trial in patients with Metastatic nonsmall cell lung carcinoma. Cancer 92:2639-2647, 2001

• 4) Shepherd FA, Dancey J, Ramlau R, et al:Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:20952103, 2000

• 5) Fossella FV, Devore R, Kerr RN, et al:Phase III trial of docetaxel versus vinorelbine or ifosphamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000
  pubmed

• 6) 武田晃司:再発非小細胞癌. Medical Practice 19:97-101, 2002
  Medical*Online

• 7) Bonfill X, Serra C, Sacristan M, et al:Second line chemotherapy for non-small cell lung cancer (Cochran Review). In:the Cochran Library, Issue 4, 2001

• 8) Kakolyris S, Papadakis E, Tsiafaki X, et al:Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 32:179-187, 2001
  pubmed

• 10) Androulakis N, Kouroussis C, Kakolyris S, et al:Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin-or docetaxel-based chemotherapy:A multicenter phase II study. Ann Oncol 9:1127-1130, 1998

• 11) Hainsworth JD, Buurris III HA Litchy S, et al:Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients:A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 88:1353-1358, 2000

• 12) Chang AY, DeVore R, Johnson D:Pilot study of vinorerubine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 23:19-21, 1996

P.195 掲載の参考文献

• 1) 矢野聖二, 兼松貴則, 曽根三郎:肺癌の増殖・浸潤・転移の分子機構と標的分子. 内科 88:798-804, 2001

• 2) 曽根三郎:分子標的治療薬. 臨床医 28:1644-1651, 2002

• 3) 中川和彦:肺癌克服に向けた新たな分子標的治療. 内科 88:805-811, 2001

• 4) Traxler P, Bold G, Buchdunger E, et al:Tyrosine Kinase lnhibitors l From rational design to clinical trials. Medicinal Research Reviews 21:499-512, 2001

• 5) Raben D, Helfrich BA, Chan D, et al:ZD 1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Seminars in Oncology 29:37-46, 2002
  pubmed

P.201 掲載の参考文献

• 1) 西村恭昌:肺がんの化学放射線治療, 映像情報. Medical 33:1187-1191, 2001
  Medical*Online

• 2) 西村恭昌:化学放射線療法:neoadjuvant chemotherapy versus concurrent chemotherapy, 癌の臨床 46:273-277, 2000

• 3) Dillman RO, Herndon J, Seagren SL, et al:Improved survival in stage III non-small-cell lung cancer:Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J Natl Cancer Inst 88:1210-1215, 1996

• 4) Le Chevalier T, Arriagada R, Quoix E, et al:Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer:First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991
  pubmed

• 5) Sause W, Kolesar P, Taylor S IV, et al:Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer:Radiation Therapy Oncology Group, Eastem Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:35&364, 2000

• 6) Furuse K, Fukuoka M, Kawahara M, et al:Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
  pubmed

• 7) Curran WJ, Scott C, Langer C, et al:Phase III comparison of sequential vs. concurrent chemoradiotherapy for pts with unresectable stage III non-small cell lung cancer (NSCLC):initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proceedings of ASCO 19:484a, 2000

• 8) Pierre F, Maurice P, Gilles R, et al:A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study) Proceedings of ASCO 20:312a, 2001

• 9) Schaake-Koning C, van den Bogaert W, Dalesio O, et al:Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524530, 1992

• 10) Uematsu M, Shioda A, Suda A, et al:Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer:a 5-year experience. Int J Radiat Oncol Biol Phys 51:666-670, 2001

• 11) Saunders M, Dische S, Barrett A, et al:Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer:mature data from the randomized multicentre trial. CHART Steering committee. Radiother Oncol 52:137-148, 1999

P.210 掲載の参考文献

• 1) 八木田旭邦:癌細胞が消えた. 二見書房, 東京, 1997

• 2) 八木田旭邦:癌細胞が消えた2. 二見書房, 東京, 2001

• 3) Kobayashi M, Fitz L, et al:Identification and Purification of Natural Killer cell stimulatory factor (NKSF), a cytokine With mul-tiple biologic effects on human lymphocytes. J Med 170:827-845, 1989

• 4) 八木田旭邦:今話題の癌民間療法 "新しい癌免疫化学療法の指針", pp246-251, 医学ジャーナル社, 大阪, 1999

• 5) 八木田旭邦, 丸山正二, 助川 寧ほか:新生血管阻害と内因性IL-12とを用いた新免疫療法-特にNKT細胞の関与について-. Biotherapy 14:433-439, 2000

• 6) 八木田旭邦, 丸山正二, 助川 寧ほか:Natural IL-12誘起剤の各種進行癌に対する作用. Biotherapy 14:33-37, 2000
  Medical*Online

• 7) 八木田旭邦:NKT細胞活性化におけるT細胞受容体とNK受容体の役割の相違. 臨床免疫 37:10-19, 2002

• 8) 西村孝司:IL-12を用いたTh 1/Th2バランスの制御と免疫病治療の応用. 最新医学 51:87-100, 1996

• 9) 西村孝司:IL-12によって活性化されるTh 1主導免疫の癌治療における意義. Biotherapy 11:820-828, 1997
  Medical*Online

• 10) Kawano T, Cui J, Koezuka Y, et al:CDld-restricted and TCR-mediated activation of V a 14NKT cells by glycosylceramide. Science 278:1626-1629, 1997

• 11) Arase N, Arase H, Park SY, et al:Association with FcRr is essential for activation signal through NKR-Pl (CD161) in NK cells and NK1. 1+cells. J Exp Med 186:1957-1963, 1997

P.216 掲載の参考文献

• 1) Lazarou J, Pomeranz BH, Corey PN:Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 279:1200-1205, 1998.
  pubmed

• 2) 中川和子, 宮島真史, 安藤正幸:薬物による間質性肺炎. 臨床医 24:2425-2429, 1998

• 3) Foucher P, Biour M, Blayac Jp, et al:Drugs that may injure the respiratory system. Eur Respir J 10:265279, 1997

• 4) Cooper JAD Jr, White DA, Matthay RA:Drug-induced pulmonary disease. Part 1:cytotoxic drugs. Am Rev Respir Dis 133:321-340, 1986

• 5) Cooper JAD Jr, White DA, Matthay RA:Drug-induced pulmonary disease. Part 2:noncytotoxic drugs. Am Rev Respir Dis 1331 48&505, 1986

• 6) Myers JL:Pathology of drug-induced lung disease. In:Katzenstein and Askin:s Surgical Pathology of Non-Neoplastic Lung Disease (eds, Katzenstein M, Askin FB), 3rd ed, pp81-111, WB Saunders, Philadelphia, 1997.

• 7) 小林 晃, 大野彰二, 杉山幸比古:薬剤性肺臓炎. 日胸 61:106-114, 2002
  Medical*Online

• 8) 近藤有好:薬剤による肺障害. (薬剤肺炎) 結核 74:33-41, 1999

• 9) Padley SPG, Adler B, Hansell DM, et al:High-resolution computed tomography of drug-induced lung disease. Clin Radiol 46:232-236, 1992

• 10) Azoulay E, Attalah H, Harf A, et al:Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity:myth or reality? Chest 120:1695-1701, 2001

• 11) Tamagawa K, Taooka Y, Maeda A, et al:Inhibitory effects of a lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 161:1279-1284, 2000
  pubmed

• 12) Wolach B, Gavrieli R, Pomeranz A:Effect of granulocyte and granulocyte macrophage colony stimulating factors (G-CSF and GM-CSF) on neonatal neutrophil functions. Pediatr Res 48:369-373, 2000
  pubmed

• 13) 小林 晃, 大野彰二, 坂東政司ほか:Chemoradiotherapyにおける放射性肺臓炎症例の検討. 肺癌 39:688, 1999

• 14) 吉村明修, 工藤翔二:肺障害とその対策. がん化学療法の有害反応対策ハンドブック 改訂版 (赤沢修吾, 栗原 稔編), pp192-200, 先端医学社, 東京, 1999

P.221 掲載の参考文献

• 1) Goto K, Nishiwaki Y, Yokoyama A, et al:Serum levels of KL6, surfactant proteins A and D are useful biomarkers for severe radiation pneumonitis. Jpn J Chest Disease 61:115-124, 2002

• 2) Goto K, Kodama T, Sekine I, et al:Serum levels of KI-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer 34:141-148, 2001

• 3) Hamada H, Kohno N, Aldyama M, et al:Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest 101:858-860, 1992

• 4) Kohno N, Hamada H, Fujioka S, et al:Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest 102:117-122, 1992
  pubmed

• 5) Takahashi H, Imai Y, Fujishima T, et al:Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur Respir J 17:481-487, 2001

• 6) Cox JD, Azarnia N, Byhardt RW, et al:Arandomized phase I/II trial of hyperfractionated radiation therapy With total doses of 60. O Gy to 79. 2 Gy:possible survival benefit with greater than or equal to 69. 6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma:report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555, 1990
  pubmed

• 7) Cox JD, Azarnia N, Byhardt RW, et al:N2 (clinical) non-small cell carcinoma of the lung:prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 20:7-12, 1991
  pubmed

• 8) Pass HI, Mitchell JB, Johnson DH, et al:Lung cancer principles and practice, 2nd ed, Philadelphia, Lippincott Williams&Wilkins, 2000

P.227 掲載の参考文献

• 1) Noda K, Nishiwaki Y, Kawahara M, et al, for the Japan Clinical Oncology Group:Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
  pubmed

• 2) Rothenberg ML, Meropal NJ, Poplin EA, et al:Mortality associated with irinotecan plus bolus fluorouracil/leucovorin:summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001

• 3) Kobayashi K, Bouscarel B, Matsuzaki Y, et al:PH dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 83:491-496, 1999
  pubmed

• 4) Ikegami T, Ha L, Latham P, et al:Intestinal Alkalization as a Possible Preventive Mechanism in Irinotecan (CPT-11)-lnduced Diarrhea. Cancer Res 62:179-187, 2002

• 5) Takeda Y, Kobayashi K, Akiyama Y, et al:Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 92:269-275, 2001
  pubmed

• 6) Takasuna K, Hagiwara T, Hirohashi M, et al:Involvement of beta-glucuronidase in intestinal microfiora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride. Cancer Research 56:3752-3757, 1996

• 7) Yokoi T, Narita M, Nagai E, et al:Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a subsrate. Jpn J Cancer Res 86:985-989, 1995

• 8) Takasuna K, Kasai Y, Kitano Y, et al:Prospective effects of kampo medicines and baicaling against intestinal toxicity of a new anticancer camptotecin derivative, irinotecan hydrochloride (CPT-11). Jpn J Cancer Res 86:978-984, 1995

• 9) Kehrer DE Sparreboom A, Verweij J, et al:Modulation of irinotecan-induced diarrhea by cotreatment With neomycin in cancer patients. Clin Cancer Res 7:1130-1141, 2001

• 10) Trifan OC, Durham WF, Salazar VS, et al:Cyclooxygenase-2 inhibition With celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPI:-11. Cancer Res 62:5778-5784, 2002

P.232 掲載の参考文献

• 1) 金倉 譲, 手島博文ほか:急性白血病における発熱原因の検討. 日血会誌 48:1514-1521, 1985

• 2) 正岡 徹:Febrile Neutropenia-日本におけるガイドライン-. 癌と化学療法 27:161-165, 2000

• 3) Schwartzentruber DJ:Neutropenic enterocolitis, In:Cancer. Principles and Practice of Oncology, 5th Edition (eds, DeVita VT Jr, Hellman S, Rosenberg SA), pp2506-2507, Lippincott-Raven, Philadelphia, USA, 1997

• 4) American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors:evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994

• 5) American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors:evidence-based clinical practice guidelines. J Clin Oncol 14:1957-1960, 1996

P.237 掲載の参考文献

• 1) 世界保健機構 (編):がんの痛みからの解放. 金原出版, 1987

• 2) がん緩和ケアに関するマニュアル. 日本ホスピス・緩和ケア研究振興財団, 2002

• 3) Twycross RG:Pain Relief in Advanced Cancer. Churchill Livingstone:London, 1990

• 4) 恒藤 曉:最新緩和医療学, pp47-50, 最新医学社, 東京, 1999

• 5) Saunders C, Sykes N:The Management of Terminal Malignant Disease, pp1-14, Edward Amold, London, 1993

• 6) 世界保健機構 (編), 武田文和訳:がんの痛みからの解放とパリアティブケア. 金原出版, 東京, 1993

• 7) Langman MJ, Weil J:Risks of bleeding peptic ulcer associated With individual non-steroidal anti-inflammatory drugs. Lancet 343 1075-1078, 1998

P.242 掲載の参考文献

• 1) 近藤晴彦, 中山治彦, 浅村尚生ほか:転移性肺腫瘍の外科治療. 日外会誌99:299-302, 1998

• 2) The intemational registry of lung metastasis:long-term results of lung metastasectomy:prognostic analyses on 5206 cases. J Thorac Cardiovasc Surg 113:37-49, 1997

• 3) Thomford NR, Wooler LB, Clagett OT:The surgical treatment of metastatic tumors in the lung. J Thorac Cardiovasc Surg 49:357-363, 1965

• 4) Horan TA, Santiago FF, Araujo LM:The benefit of pulmonary metastectomy for bone and soft tissue sarcoma. Int Surg 85:185 189, 2000

• 5) 森岡秀夫, 矢部啓夫, 山田睦雄ほか:悪性骨・軟部腫瘍肺転移に対する外科的治療. 日整会誌 73:S475, 1999

• 6) 近藤 丘, 羽島正仁, 藤村重文ほか:骨肉腫肺転移における外科治療成績と予後因子の検討. 胸部外科 49:896-901, 1996

• 7) Bacci G, Mercuri M, Briccoli A, et al:Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 79:245-254, 1997
  pubmed

• 8) Martini N, Melamed MR:Multiple primary lung cancers. J Thorac Cardiovasc Surg 70:606612, 1975

• 9) Matsuzoe D, Hideshima T, Ohsima K, et al:Discrimination of double primary lung cancer from intrapulmonary metastasis by P53 gene mutation 79:1549-1552, 1999

• 10) Rosengart TK, Martini N, Ghosn P, et al:Multiple primary lung carcinomas:prognosis and treatment. Ann Thorac Surg 52:773-779, 1991
  pubmed